Compare Amgen, Inc. (AMGN) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs T Rowe Price Group Inc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while T Rowe Price Group Inc trades at $118.55 (market cap $25.40B). The key difference: Amgen, Inc. is far larger — about 7.7× T Rowe Price Group Inc's market cap, and T Rowe Price Group Inc pays the higher dividend (4.39%). Which is the better fit depends on your goals.
| AMGN | TROW | |
|---|---|---|
Market Cap | $196.12B | $25.40B |
Sector | Health | Financials |
52-Week High | $388.16 | $120.16 |
52-Week Low | $271.18 | $86.19 |
Enterprise Value | $241.41B | $22.11B |
Dividend Yield | 2.77% | 4.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
T. Rowe Price (TROW) trades at $118.55, up 1.28% on the day, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a 28.28% net income margin and a P/E of 12.72, indicating potential undervaluation. Recent earnings have mostly beaten expectations, and the company maintains robust cash flow, supporting a sustainable dividend. Strategic enhancements to its institutional business and positive media coverage highlight ongoing growth initiatives.
The outlook for TROW is positive, driven by solid fundamentals and strategic positioning, though investor caution is warranted given the majority hold rating from analysts and competitive pressures in asset management. Upside potential exists if the company continues to exceed earnings estimates and manage equity outflows effectively, but macroeconomic volatility remains a key risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
